Pacific Biosciences Of California (PACB) Research & Development (2010 - 2026)

Pacific Biosciences Of California has reported Research & Development for 17 years, with the latest figure at $19.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 32.51% year-over-year to $19.6 million; the trailing twelve-month figure through Mar 2026 stood at $87.9 million (down 27.1% YoY), and the FY2025 full-year result was $97.3 million, down 27.88% from the prior year.
• Research & Development for Q1 2026 stood at $19.6 million, down from $22.9 million in the prior quarter.
• The five-year high for Research & Development was $52.9 million in Q1 2022, with the low at $19.6 million in Q1 2026.
• Average Research & Development over 5 years is $37.2 million, with a median of $42.6 million recorded in 2022.
• Year-over-year, Research & Development soared 157.63% in 2022 and tumbled 46.3% in 2024.
• Tracing PACB's Research & Development over 5 years: stood at $42.6 million in 2022, then gained by 4.51% to $44.5 million in 2023, then tumbled by 38.34% to $27.5 million in 2024, then decreased by 16.7% to $22.9 million in 2025, then decreased by 14.3% to $19.6 million in 2026.
• The last three Research & Development figures came in at $19.6 million (Q1 2026), $22.9 million (Q4 2025), and $22.8 million (Q3 2025), per Business Quant data.

Peer Comparison